Amyloid-Beta biomarker antibody program (Aβ 1–16)
Category
Diagnostics and Personalised Medicine
Register type
Biotech Sanitaria
Company name
Product / Service
Amyloid-Beta biomarker antibody program (Aβ 1–16)
Type
Diagnostic
Therapeutic area
Sistema nervioso central
Properties/Indication
High-specificity monoclonal antibodies targeting the Aβ 1–16 peptide, designed for selective and reproducible detection of Alzheimer’s disease–related biomarkers. These antibodies are engineered for high affinity and minimal cross-reactivity, optimized for integration into ultrasensitive immunoassay technologies. The program aims to support early detection, biomarker research, and disease monitoring in Alzheimer’s disease and related neurodegenerative disorders.
Application
Intended for use as in vitro diagnostic and research reagents, including integration into ultrasensitive immunoassays for detection and quantification of Aβ 1–16. Applications include clinical and translational research, biomarker studies, assay development and validation, and use as analytical or reference reagents for monitoring Alzheimer’s disease–related peptides in biological samples.
Development phase
R&D
Phases developed in Spain
R&D
Research location
España